RARE DISEASERESEARCH ATLAS

ORPHA:86850

Myeloid sarcoma

low confidenceDisorder

Also known as: Chloroma · Extramedullary myeloid tumor · Granulocytic sarcoma

Publications

5,715

Trials

12

Interventional, condition-specific

Researchers

1,169

Distinct authors in sample

Gene link

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Myeloid sarcoma is a rare solid tumor of the myelogenous cells occurring in an extramedullary site.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

chloroma · extramedullary myeloid tumor · extramedullary myeloid tumour · myeloid sarcoma · sarcoma, myeloid, malignant

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    5,715 matched papers (2,473 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    12 matched on ClinicalTrials.gov (4 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

12

Drugs / clinical candidates · MONDO_0006861

CTD chemicals (MyDisease.info)

1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Melphalan · marker/mechanism

MyDisease.info · MONDO:0006861

Literature

Is anyone studying this?

5,715

5,715 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

5,715 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

2,473 in the last 10 years · low confidence

Phrase hits: 5,714 · MeSH hits: 12

Open Europe PMC search

Who's working on it?

1,169

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Liu Y5 papers · 2026

    Hematology Oncology Center, Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, National Center for Children's Health in Baoding, Baoding, 071000, China.

    Papers in Europe PMC
  2. 02
    Wang X5 papers · 2026

    Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China.

    Papers in Europe PMC
  3. 03
    Zhang Y5 papers · 2026

    West China Hospital, Sichuan University, Chengdu, China.

    Papers in Europe PMC
  4. 04
    He Y3 papers · 2025

    Department of Clinical and Experimental Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.

    Papers in Europe PMC
  5. 05
    Li Z3 papers · 2026

    The Ohio State University Columbus, OH United States.

    Papers in Europe PMC
  6. 06
    Loghavi S3 papers · 2026

    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

    Papers in Europe PMC
  7. 07
    Thapa S3 papers · 2026

    The University of Oklahoma College of Medicine, University of Oklahoma Health Sciences Center, 940 Stanton L Young Blvd #357, Oklahoma City, OK 73104, USA.

    Papers in Europe PMC
  8. 08
    Yang J3 papers · 2025

    Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, School of Medicine Westlake University Hangzhou Zhejiang China.

    Papers in Europe PMC
  9. 09
    Abaza H2 papers · 2026

    The Ohio State University Wexner Medical Center Columbus, Ohio United States.

    Papers in Europe PMC
  10. 10
    Abiko K2 papers · 2025

    2Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Ishikawa, 920-8641, Japan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

12

interventional trials for this specific condition

12 interventional trials matched this specific condition name; 4 currently recruiting in our sample. 1,643 trials are registered for sarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

12 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 93.2th percentile).

low confidence · 93.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

12 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: sarcoma

1,643

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (4)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Myeloid sarcoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Myeloid sarcoma" OR "Chloroma" OR "Extramedullary myeloid tumor" OR "Granulocytic sarcoma" OR "extramedullary myeloid tumour" OR "sarcoma, myeloid, malignant"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Sarcoma, Myeloid

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Myeloid sarcoma" OR "Chloroma" OR "Extramedullary myeloid tumor" OR "Granulocytic sarcoma" OR "extramedullary myeloid tumour" OR "sarcoma, myeloid, malignant" OR "Sarcoma, Myeloid"

Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 12 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"sarcoma"

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (5715) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T03:11:58.787Z